Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistance to anti‐PD‐1 therapy. This single‐arm phase 2 trial (NCT040...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Dingwei, Liu, Jiyan, Zhou, Aiping, Zou, Qing, Li, Hanzhong, Fu, Cheng, Hu, Hailong, Huang, Jian, Zhu, Shaoxing, Jin, Jie, Ma, Lulin, Guo, Jianming, Xiao, Jun, Park, Se Hoon, Zhang, Dahong, Qiu, Xiusong, Bao, Yuanyuan, Zhang, Lilin, Shen, Wei, Bi, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780053/
https://www.ncbi.nlm.nih.gov/pubmed/33047430
http://dx.doi.org/10.1111/cas.14681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780053/
https://www.ncbi.nlm.nih.gov/pubmed/33047430
http://dx.doi.org/10.1111/cas.14681

Ejemplares similares